Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
Matinas BioPharma & BioNTech Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines April 11, 2022
Matinas BioPharma and BioNTech SE recently announced they have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and….
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations March 29, 2022
Gb Sciences, Inc. recently announced its sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was….
Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility March 22, 2022
Blue Water Vaccines Inc. recently announced its licensing partner, Cincinnati Children’s Hospital Medical Center, or CCHMC, has published a research...NASAL DELIVERY - Improving Nasal Drug Delivery With Permeation Enhancing Technology March 1, 2022
Stuart Madden, PhD, focuses on the use of alkylsaccharides as absorption enhancers for nasal delivery of a wide range of drug types.
ORGAN-ON-A-CHIP - A Novel Way to Accurately Test Delivery of Non-Standard Formulations January 17, 2022
David Hughes, PhD, says ultimately, the goal of OOC technology is to improve the translatability of data between the lab and the clinic. Through a lung-on-a-chip approach, it is possible to recreate the histoarchitecture, phenotype, and function of bronchial and alveolar areas of the lung.
PharmaTher Enters Process Development Agreement Eith LTS for Ketamine Microneedle Patch December 20, 2021
PharmaTher Holdings Ltd. and LTS LOHMANN Therapie-Systeme AG recently announced they have entered into a process development agreement for the clinical trial scale up of PharmaTher’s proprietary….
Gb Sciences Accelerates Drug Development Via Innovative Biopharma Technology & Strategic Partnerships November 29, 2021
Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company Gb Sciences has taken innovative steps to speed up….
Quris Closes Critical Drug Development Gaps With New Clinical Prediction AI Platform October 22, 2021
Quris recently launched the first clinical prediction AI platform to predict which drug candidates will safely work in humans – significantly improving efficacy and cutting drug development….
TFF Pharmaceuticals & Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody Neutralizes SARS-CoV-2 Infection & Reduces Viral Load October 14, 2021
TFF Pharmaceuticals, Inc. and Augmenta Bioworks recently announced the publication of a research paper highlighting positive preclinical study results of...DEVICE DEVELOPMENT - Selecting Drug Delivery Systems for Higher Doses, Higher Viscosities & Lower Risk October 4, 2021
Nicolas Bralet and Megan Lan, MBA, MA, discuss how companies can de-risk their device selection as they bring this new generation of high-volume, high-viscosity biologics to market.
DRUG DEVELOPMENT - Simplifying the Drug Development Journey October 4, 2021
Fran DeGrazio explains how experienced and focused collaborators can provide guidance, support services, manpower, and intellect to make it easier to achieve all the goals needed in delivering a drug to a patient.
AzurRx BioPharma Announces Acquisition of First Wave Bio & its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications September 15, 2021
AzurRx BioPharma, Inc. recently announced it has entered a definitive agreement to acquire First Wave Bio, Inc. in a stock and cash transaction valued at….
DELIVERY DEVICE - Aerosol Deposition Characterization of Innovative PureHale® Technology Targeting the Upper Airways August 26, 2021
Degenhard Marx, PhD, Fotos Stylianou, PhD, and Stavros Kassinos, PhD, explain how PureHale provides a modern device option for the delivery of a fine mist for a variety of solutions to only the upper respiratory tract without significant deposition in the lungs and lower airways.
Dyadic & Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate & C1 Technology for Protein-Based Coronavirus Vaccines & Therapeutics August 17, 2021
Dyadic International, Inc. and Sorrento Therapeutics, Inc. recently announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for….
Catalent to Supply Edenbridge Pharmaceuticals With a Fast-Dissolve Zydis Formulation of Glycopyrrolate Intended as Adjunctive Therapy for Patients With Peptic Ulcer August 10, 2021
Catalent recently announced it has signed a commercial supply agreement with Edenbridge Pharmaceuticals, LLC, for a novel formulation of glycopyrrolate...Lantern Pharma & Allarity Therapeutics Enter Into Agreement for Future Clinical Development of Irofulven July 28, 2021
Allarity Therapeutics A/S and Lantern Pharma Inc. recently announced they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full….
eTheRNA immunotherapies & Quantoom Biosciences Announce Strategic Collaboration for the Development of a Novel RNA Production June 30, 2021
eTheRNA immunotherapies NV and Quantoom Biosciences S.A. recently announced they are to collaborate on the development of a revolutionary RNA production system (RPS) for both research and GMP-grade material…..
Vectura Signs Preclinical Development Agreement With Incannex June 23, 2021
Vectura Group plc recently announced it has signed an agreement with Incannex Healthcare Limited, an Australian cannabinoid medicines development company, to provide preclinical development services for….
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Meeting Demand for Biologics & Specialty Drugs June 2, 2021
Contributor Cindy Dubin highlights the formulation development and manufacturing offerings from some of the leading CDMOs to address a myriad of challenges – from complex compounds to poor solubility to dual-release profiles.
OPEN INNOVATION PLATFORM - Beyond the Rule of Five: Scouting for Novel Formulation Approaches to Enable the Subcutaneous Application of Molecules With Poor Drug-Like Properties in Preclinical Research – Facilitated Through opnMe.com June 1, 2021
Ines Truebenbach, PhD; Menorca Chaturvedi, PhD; Markus Koester, PhD; and Achim Grube, PhD, are looking for proposals that would provide innovative formulation approaches to facilitate the subcutaneous application of bRo5 molecules in a preclinical setting.
Company Profiles
Lyophilization Technology, Inc.
Lyophilization Technology, Inc. 30 Indian Drive Ivyland, PA 18974-1431 T: (215) 396-8373 F: (215) 396-8375 E: inquiry@lyo-t.com W: www.lyotechnology.com WHO...DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products
Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.
